YZYuebao Zhang

Yuebao Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuebao Zhang has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Yizhou Dong

    Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, USA

    8 shared publications
  • Binbin Deng

    Center for Electron Microscopy and Analysis, The Ohio State University, Columbus, OH 43212, United States

    7 shared publications
  • David W. McComb

    The Ohio State University

    7 shared publications
  • Diana D. Kang

    Icahn Genomics Institute, Precision Immunology Institute, Department of Immunology and Immunotherapy, Department of Oncological Sciences, Tisch Cancer Institute, Biomedical Engineering and Imaging Institute, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, United States

    7 shared publications
  • Haoyuan Li

    Icahn Genomics Institute, Precision Immunology Institute, Department of Immunology and Immunotherapy, Department of Oncological Sciences, Tisch Cancer Institute, Biomedical Engineering and Imaging Institute, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, United States

    6 shared publications
  • Dinglingge Cao

    Icahn Genomics Institute, Precision Immunology Institute, Department of Immunology and Immunotherapy, Department of Oncological Sciences, Tisch Cancer Institute, Biomedical Engineering and Imaging Institute, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, United States

    5 shared publications

Latest Publications

  • Open Access

    Engineering drug-responsive replication machinery for precise control of self-amplifying RNA

    by Parisa Yousefpour, Justin R. Gregory, Kristen Si, Jan Lonzaric, Yingzhong Li, Junmin Wang, Kashif Qureshi, Amir Ledbetter, Mariane B. Melo, Alexander Hostetler, et al.

    Precise, reversible control of gene expression from self‑amplifying RNA (saRNA) remains difficult, limiting the therapeutic flexibility of this otherwise potent platform. Although alphavirus‑derived saRNAs encode non‑structural proteins that drive RNA replication and offer an intrinsic regulatory point, no existing approach has enabled direct, drug‑dependent control of this machinery for high‑fidelity modulation of expression. Here we engineer saRNA constructs whose replication is activated by the approved small‑molecule drug trimethoprim, using drug‑responsive degradation domains fused to individual non‑structural proteins to regulate self‑amplification. As each replication protein contributes differently to RNA copying, we systematically screened fusion configurations and identified an optimal design combining modified replication proteins with a regulated payload. This construct achieved more than a 10 4 ‑fold difference between on and off states with negligible background expression. In mice, oral trimethoprim enabled tunable, reversible and temporally programmed expression patterns. When encoding a human immunodeficiency virus antigen, an escalating trimethoprim regimen enhanced germinal centre responses, a key determinant of antibody affinity maturation. This drug‑regulated saRNA platform provides a controllable and clinically compatible strategy for vaccines, immunotherapies and gene therapies.


  • Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer

    by Furong Huang, Fuwen Yuan, Kexin Li, Ya Cui, Lei Li, Wenbin Ye, Zhifen Cui, Jingyue Yan, Qiang Chen, Christopher Nicchitta, et al.

    Immune-cold tumours such as prostate cancer often resist immune checkpoint therapies (ICT) due to impaired antigen presentation via major histocompatibility complex class I (MHC-I). While MHC-I downregulation is a common immune evasion mechanism, no approved therapies selectively restore MHC-I expression in tumours. We developed a programmable RNA engineering platform, termed the 3'UTR CRISPR/dCas13 Engineering System (3'UTRCES), to precisely manipulate mRNA alternative polyadenylation (APA) in vivo. We identified tumour-specific 3'UTR shortening of the E3 ligase adaptor SPSB1 as a driver of MHC-I degradation via SPSB1-mediated ubiquitination, without affecting PD-L1. Lipid nanoparticle (LNP)-delivered 3'UTRCES reversed SPSB1 3'UTR shortening, restored MHC-I expression and sensitized tumours to ICT in syngeneic mice. These effects were elicited by MHC-I-dependent increases in CD8 T cell infiltration and antitumour cytotoxic activity. Our findings reveal APA-driven MHC-I suppression as a previously unrecognized mechanism of immune escape and establish LNP-3'UTRCES as a versatile platform for post-transcriptional RNA engineering in cancer.


  • Aminophosphonate-Derived lipid nanoparticles enable circular RNA delivery for functional recovery after spinal cord injury

    by Haoyuan Li, Yuebao Zhang, Yichen Zhong, Kaiyuan Guo, Shi Du, Yonger Xue, Chang Wang, Siyu Wang, Dean Shuailin Chen, Zhengwei Liu, et al.


  • Furan-Derived Lipid Nanoparticles for Transporting mRNA to the Central Nervous System

    by Zhengwei Liu, Yuebao Zhang, Haoyuan Li, Kaiyuan Guo, Meng Tian, Dinglingge Cao, Diana D. Kang, Yonger Xue, Xucheng Hou, Chang Wang, et al.

    Delivery of mRNA (mRNA) to the central nervous system (CNS) remains a significant challenge. Herein, we design a library of furan-derived lipids and, to our knowledge, for the first time, leverage the meningeal lymphatic vessels (MLVs) route to achieve efficient delivery of mRNA to the brain. These furan-derived lipids were engineered with different furan cores, functional groups, and tails. We found that tetrahydrofuran (THF)-derived lipid nanoparticles (LNPs) generally displayed exceptional mRNA delivery compared to their furan-based counterparts. Specifically, LNPs formulated with four-acetal-tail mono-THF-derived lipid F10T5 and four-acetal-tail di-THF-derived lipid F11T6 demonstrated significantly higher mRNA delivery efficiency to the brain compared with FDA-approved SM102 LNPs. The data revealed that these LNPs bypassed the blood-brain barrier (BBB) via the lymphatic pathway, traveling from deep cervical lymph nodes (dCLNs) to the meninges and subsequently entering brain cells. Collectively, this work provides valuable insights into engineering LNPs and exploring alternative approaches for the delivery of mRNA to the brain.


  • Open Access

    LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment

    by Yonger Xue, Xucheng Hou, Yichen Zhong, Yuebao Zhang, Shi Du, Diana D. Kang, Leiming Wang, Chang Wang, Haoyuan Li, Siyu Wang, et al.

    Lipid nanoparticle (LNP)-mRNA vaccines have demonstrated protective capability in combating SARS-CoV-2. Their extensive deployment across the global population leads to the broad presence of T-cell immunity against the SARS-CoV-2 spike protein, presenting an opportunity to harness this immunological response as a universal antigen target for cancer treatment. Herein, we design and synthesize a series of amino alcohol- or amino acid-derived ionizable lipids (AA lipids) and develop an LNP-RNA-based antigen presentation platform to redirect spike-specific T-cell immunity against cancer in mouse models. First, in a prime-boost regimen, AA2 LNP encapsulating spike mRNA elicit stronger T-cell immunity against the spike epitopes compared to FDA-approved LNPs (ALC-0315 and SM-102), highlighting the superior delivery efficiency of AA2 LNP. Next, AA15V LNP efficiently delivers self-amplifying RNAs (saRNAs) encoding spike epitope-loaded single-chain trimer (sSE-SCT) MHC I molecules into tumor tissues, thereby inducing the presentation of spike epitopes. Our results show that a single intratumoral (i.t.) treatment of AA15V LNP-sSE-SCTs suppresses tumor growth and extends the survival of B16F10 melanoma and A20 lymphoma tumor-bearing mice vaccinated with AA2 LNP-spike mRNA. Additionally, AA15V LNP-sSE-SCTs enable SE-SCT expression in ex vivo human glioblastoma and lung cancer samples, suggesting its potential in clinical translation.


  • Top Cited Papers

    Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system

    by Chang Wang, Yonger Xue, Tamara Markovic, Haoyuan Li, Siyu Wang, Yichen Zhong, Shi Du, Yuebao Zhang, Xucheng Hou, Yang Yu, et al.

    The systemic delivery of mRNA molecules to the central nervous system is challenging as they need to cross the blood–brain barrier (BBB) to reach into the brain. Here we design and synthesize 72 BBB-crossing lipids fabricated by conjugating BBB-crossing modules and amino lipids, and use them to assemble BBB-crossing lipid nanoparticles for mRNA delivery. Screening and structure optimization studies resulted in a lead formulation that has substantially higher mRNA delivery efficiency into the brain than those exhibited by FDA-approved lipid nanoparticles. Studies in distinct mouse models show that these BBB-crossing lipid nanoparticles can transfect neurons and astrocytes of the whole brain after intravenous injections, being well tolerated across several dosage regimens. Moreover, these nanoparticles can deliver mRNA to human brain ex vivo samples. Overall, these BBB-crossing lipid nanoparticles deliver mRNA to neurons and astrocytes in broad brain regions, thereby being a promising platform to treat a range of central nervous system diseases.


  • Open Access

    Accelerating diabetic wound healing by ROS-scavenging lipid nanoparticle–mRNA formulation

    by Siyu Wang, Yuebao Zhang, Yichen Zhong, Yonger Xue, Zhengwei Liu, Chang Wang, Diana D. Kang, Haoyuan Li, Xucheng Hou, Meng Tian, et al.

    Current treatment options for diabetic wounds face challenges due to low efficacy, as well as potential side effects and the necessity for repetitive treatments. To address these issues, we report a formulation utilizing trisulfide-derived lipid nanoparticle (TS LNP)-mRNA therapy to accelerate diabetic wound healing by repairing and reprogramming the microenvironment of the wounds. A library of reactive oxygen species (ROS)-responsive TS LNPs was designed and developed to encapsulate interleukin-4 (IL4) mRNA. TS2-IL4 LNP-mRNA effectively scavenges excess ROS at the wound site and induces the expression of IL4 in macrophages, promoting the polarization from the proinflammatory M1 to the anti-inflammatory M2 phenotype at the wound site. In a diabetic wound model of db/db mice, treatment with this formulation significantly accelerates wound healing by enhancing the formation of an intact epidermis, angiogenesis, and myofibroblasts. Overall, this TS LNP-mRNA platform not only provides a safe, effective, and convenient therapeutic strategy for diabetic wound healing but also holds great potential for clinical translation in both acute and chronic wound care.


  • Top Cited Papers
    Open Access

    LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing

    by Yonger Xue, Yuebao Zhang, Yichen Zhong, Shi Du, Xucheng Hou, Wenqing Li, Haoyuan Li, Siyu Wang, Chang Wang, Jingyue Yan, et al.

    Adipose stem cells (ASCs) have attracted considerable attention as potential therapeutic agents due to their ability to promote tissue regeneration. However, their limited tissue repair capability has posed a challenge in achieving optimal therapeutic outcomes. Herein, we conceive a series of lipid nanoparticles to reprogram ASCs with durable protein secretion capacity for enhanced tissue engineering and regeneration. In vitro studies identify that the isomannide-derived lipid nanoparticles (DIM1T LNP) efficiently deliver RNAs to ASCs. Co-delivery of self-amplifying RNA (saRNA) and E3 mRNA complex (the combination of saRNA and E3 mRNA is named SEC) using DIM1T LNP modulates host immune responses against saRNAs and facilitates the durable production of proteins of interest in ASCs. The DIM1T LNP-SEC engineered ASCs (DS-ASCs) prolong expression of hepatocyte growth factor (HGF) and C-X-C motif chemokine ligand 12 (CXCL12), which show superior wound healing efficacy over their wild-type and DIM1T LNP-mRNA counterparts in the diabetic cutaneous wound model. Overall, this work suggests LNPs as an effective platform to engineer ASCs with enhanced protein generation ability, expediting the development of ASCs-based cell therapies.


  • Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy

    by Yuebao Zhang, Xucheng Hou, Shi Du, Yonger Xue, Jingyue Yan, Diana D. Kang, Yichen Zhong, Chang Wang, Binbin Deng, David W. McComb, et al.

    Effective cancer immunotherapy is usually blocked by immunosuppressive factors in the tumour microenvironment, resulting in tumour promotion, metastasis and recurrence. Here we combine lipid nanoparticle–mRNA formulations and dendritic cell therapy (named CATCH) to boost the cancer–immunity cycle via progressive steps to overcome the immunosuppressive tumour microenvironment. Multiple types of sugar-alcohol-derived lipid nanoparticles are conceived to modulate the cancer–immunity cycle. First, one type of lipid nanoparticle containing CD40 ligand mRNA induces robust immunogenic cell death in tumoural tissues, leading to the release of tumour-associated antigens and the expression of CD40 ligand. Next, dendritic cells engineered by another type of lipid nanoparticle encapsulating CD40 mRNA are adoptively transferred, which are then activated by the CD40 ligand molecules in tumoural tissues. This promotes the secretion of multiple cytokines and chemokines, and the upregulation of co-stimulatory molecules on dendritic cells, which are crucial for reprogramming the tumour microenvironment and priming the T-cell responses. After dendritic cells present tumour-associated antigens to T cells, all the above stepwise events contribute to boosting a potent tumour-specific T-cell immunity that eradicates established tumours, suppresses distal lesions and prevents tumour rechallenge.